Last reviewed May 10, 2026
Quick answer: Is bleeding after menopause always cancer? No. About 1 in 10 cases of postmenopausal bleeding turns out to be endometrial cancer (ACOG Practice Bulletin 128). The other 9 are usually endometrial atrophy, polyps, or HRT-related. Either way, every episode of postmenopausal bleeding needs a transvaginal ultrasound within 1 to 2 weeks. An endometrial thickness of 4 mm or less has approximately 99 percent negative predictive value for cancer. ClearedRx does not replace your gynecologist for bleeding workup — but if HRT is on the table after evaluation, we can help with that piece.
The 60-second version
The fear hits before the question
Your period stopped two years ago. Now there is spotting on the toilet paper, or a smear of brown on your underwear, or a single bright-red drop in the bowl. The fear hits before the question. The first thing your phone hands you, in red letters, is the word cancer. The second thing — buried four results down — is the boring sentence about endometrial atrophy that almost certainly explains what is actually happening. Both are true. Neither is sufficient.
Is bleeding after menopause always cancer? No. Is it ever cancer? Yes — in about 1 in 10 women who present with postmenopausal bleeding, the diagnosis turns out to be endometrial carcinoma, per ACOG Practice Bulletin No. 128 and confirmed by the 2018 cohort review by Goodman and colleagues in Obstetrics & Gynecology. The other 9 are almost always benign. The job of this article is to lay out the math without minimizing the 10 percent and without catastrophizing the 90 — and to tell you exactly which test you need first.
This is not the article that says "always see a doctor" and ends there (true, but uselessly vague). It is also not the article that says "usually nothing" and sends you back to scrolling (technically true, occasionally dangerous). Postmenopausal bleeding is a symptom with a 90 percent benign answer and a 10 percent serious answer, and the only honest way to write about it is to give you both numbers, the workup that distinguishes them, and the timing that protects you either way.
What the bleeding usually is
Before the workup, here is the prior probability — what postmenopausal bleeding most often turns out to be once a clinician has completed the evaluation. Pooled cohort numbers from ACOG Practice Bulletin 128 and the Goodman 2018 review break down the 90 percent of benign cases into a small number of repeating diagnoses. Asked another way: if you are wondering "is bleeding after menopause always cancer," the 90 percent of women who hear "no" hear one of these five answers instead.
1. Endometrial atrophy (50–60% of all postmenopausal bleeding)
The single most common cause. After menopause, circulating estradiol drops to roughly 10 to 20 pg/mL — well below the 50 to 200 pg/mL range of the reproductive years. The endometrium and the vaginal epithelium both thin in response. Thin tissue develops small surface erosions and tiny vessel breaks that produce light spotting, often after intercourse, after a bowel movement, or for no obvious reason at all. On transvaginal ultrasound, an atrophic endometrium typically measures 4 mm or less — a finding that, by itself, has roughly 99 percent negative predictive value for endometrial cancer. The fix for the underlying tissue is low-dose vaginal estrogen, which restores lubrication, blood flow, and pH; see our companion piece on genitourinary syndrome of menopause for the broader picture.
2. Endometrial and cervical polyps (10–15%)
Polyps are benign focal overgrowths of the endometrial lining or the cervical canal that can bleed when their fragile vessels are disrupted. Endometrial polyps are common in postmenopausal women — found in roughly 10 percent of asymptomatic postmenopausal women on systematic ultrasound — and the bleeding ones are typically removed by hysteroscopic polypectomy, an outpatient procedure. Most polyps are benign. A small percentage harbor atypical hyperplasia or carcinoma, which is why bleeding polyps are removed and analyzed rather than left alone.
3. Hormone-replacement-therapy-related bleeding (10–15%)
Cyclic combined HRT is designed to produce a withdrawal bleed each cycle; continuous combined HRT is designed to produce no bleed at all but commonly causes irregular spotting in the first 3 to 6 months while the endometrium adjusts. The North American Menopause Society 2022 Hormone Therapy Position Statement is explicit on the timing rule: spotting in the first 3 to 6 months of HRT is usually benign, but new or persistent bleeding after 6 months on a stable regimen warrants the same workup as bleeding off HRT entirely.
4. Submucous fibroids (~5%)
Uterine fibroids — leiomyomas — that sit underneath the endometrium can bleed when their surface vessels rupture. Most fibroids shrink after menopause as estrogen drops, but submucous fibroids that were present before menopause can persist and continue to bleed. Diagnosis is by ultrasound; treatment ranges from observation to hysteroscopic resection depending on size and symptoms.
5. Vaginal-atrophy friction bleeding (small but real %)
Genitourinary syndrome of menopause (GSM) thins the vaginal epithelium itself — separate from the endometrium — and the resulting tissue can bleed lightly with intercourse, with a tampon-like exam, or with vigorous wiping. This bleeding originates from the vaginal wall, not the uterus, and is typically scant, bright red, and tightly correlated with a triggering event. It is part of the same atrophy spectrum and responds to vaginal estrogen. The workup still includes transvaginal ultrasound — clinically distinguishing vaginal-source from uterine-source bleeding requires speculum exam, and any uterine source needs the full workup.
What it could be — endometrial cancer (and why staging is the lever)
Now the 10 percent. The honest answer to "is bleeding after menopause always cancer" is no, but the honest answer to "is it ever cancer" is yes — in the meaningful minority of cases, the diagnosis is endometrial carcinoma. Endometrial cancer is the most common gynecologic malignancy in the United States — about 67,000 new cases and 13,000 deaths per year per the National Cancer Institute SEER program — and the great majority of cases first announce themselves with exactly this symptom: bleeding after menopause. That is, statistically, the good news. Endometrial cancer is one of the most curable cancers when caught at Stage I — confined to the uterus — because the symptom (bleeding) appears early in the disease course rather than late. The clinical lesson is that the workup, not the genetics, is what shifts the prognosis.
Stage-by-stage 5-year survival from the SEER database: Stage I (cancer confined to the uterus): >95 percent. Stage II (extension to cervical stroma): roughly 70 to 75 percent. Stage III (regional spread): roughly 50 to 65 percent. Stage IV (distant metastasis): roughly 15 to 25 percent. The cliff between Stage I and Stage III is dramatic — and the lever that keeps a postmenopausal-bleeding patient on the Stage I side of that cliff is the time elapsed between first bleed and first transvaginal ultrasound. ACOG recommends evaluation within 1 to 2 weeks of presentation; that timing is not bureaucratic, it is biology.
Risk factors that move you up the prior
The probability that a given postmenopausal bleed is endometrial cancer is not 9 percent for every woman — it is 9 percent on average, with substantial variation around individual risk profiles. The classic ACOG risk factors that raise endometrial cancer probability above baseline:
- Obesity (BMI ≥30) — adipose tissue converts androgens to estrogens via aromatase, producing chronic unopposed estrogen exposure. The single largest modifiable risk factor for endometrial cancer in the United States.
- Unopposed estrogen exposure — estrogen-only HRT in a woman with an intact uterus, prolonged anovulation in late perimenopause, polycystic ovary syndrome, estrogen-secreting ovarian tumors.
- Tamoxifen — the breast-cancer adjuvant has weak estrogenic effect on the endometrium and roughly doubles endometrial cancer risk over 5 years of use.
- Lynch syndrome — hereditary nonpolyposis colorectal cancer carries a lifetime endometrial cancer risk of roughly 40 to 60 percent.
- Late menopause (final menstrual period after age 55) and nulliparity (never been pregnant) — both proxies for cumulative endometrial estrogen exposure.
- Diabetes and metabolic syndrome — independently raise risk, partly through obesity-mediated and partly through insulin-related pathways.
- Years since the final menstrual period — bleeding 5 or more years after menopause carries a higher cancer probability than bleeding in the first postmenopausal year (Goodman 2018).
Risk factors raise the prior. They do not change the workup. Every postmenopausal bleed gets the same first test — transvaginal ultrasound — regardless of risk profile, and the post-test probabilities are what individualize the next step.
What 90 percent and 10 percent actually mean for the next 2 weeks
Across pooled North American and European cohorts (ACOG Practice Bulletin 128 + Goodman 2018), of every 100 women who present to a clinician with postmenopausal bleeding:
The 9 cancer cases are not randomly distributed across the 100. They cluster on the obese-and-late-postmenopausal end of the population, and they are picked out by the transvaginal ultrasound's endometrial-stripe measurement: roughly 99 percent of cancers have an endometrial stripe greater than 4 mm. That means a woman with a thin endometrial stripe and benign biopsy can be reassured, and a woman with a thick stripe gets the prompt biopsy that catches the disease at Stage I.
The protocol every woman should know
This is the workup ACOG and the American Institute of Ultrasound in Medicine recommend for any postmenopausal bleed. It is the same protocol whether the bleeding was a single drop, a single episode, or a recurrent pattern; whether you are 1 year out from menopause or 25; whether you are on HRT or not. The order is what matters, because each test changes the prior probability for the next.
Step 1: Transvaginal ultrasound (TVUS)
The first-line test. A small probe is placed in the vagina (typically more comfortable than a transabdominal ultrasound, and far more accurate for endometrial measurement) and the endometrial stripe — the combined thickness of the front and back walls of the endometrium — is measured at its widest point. The clinical decision rule:
- Endometrial stripe ≤4 mm: ~99 percent negative predictive value for endometrial cancer. In a woman with a single bleeding episode and a clear ultrasound, expectant management is reasonable.
- Endometrial stripe >4 mm: proceed to endometrial biopsy.
- Endometrial stripe ≤4 mm but bleeding persists or recurs: proceed to endometrial biopsy regardless of stripe thickness.
- Endometrial stripe cannot be measured (e.g., fibroid distortion, unable to visualize): proceed to biopsy or hysteroscopy.
Step 2: Endometrial biopsy
Office-based, no anesthesia, typically 5 to 10 minutes. A thin pipelle catheter passes through the cervix and aspirates a sample of endometrial tissue, which is sent to pathology. Sensitivity for endometrial cancer is roughly 90 to 95 percent in a postmenopausal patient. The procedure is mildly to moderately uncomfortable for most women (cramp-like for 30 to 60 seconds during the sample); ibuprofen 30 to 60 minutes beforehand helps. A normal biopsy on a thin stripe is highly reassuring; a finding of atypical hyperplasia or carcinoma triggers gynecologic-oncology referral.
Step 3: Hysteroscopy with directed biopsy
If the office biopsy is non-diagnostic (insufficient tissue), or if bleeding persists despite a normal biopsy, the next step is hysteroscopy — a thin camera introduced through the cervix to visualize the uterine cavity directly, with targeted biopsy of any abnormal area. Performed in office (some) or operating room (most). The combined TVUS + biopsy + hysteroscopy pathway has a near-100 percent sensitivity for endometrial cancer and structural sources of bleeding.
Timing: 1 to 2 weeks, not "we'll see"
ACOG explicitly recommends the workup be initiated within 1 to 2 weeks of the bleeding episode rather than waiting to see if it recurs. The reasoning is the survival math: the time-to-diagnosis from first symptom to biopsy is the lever that determines whether a cancer is caught at Stage I (>95 percent 5-year survival) or at Stage III (50 to 65 percent). If the first phone call to a gynecologist returns an appointment 6 weeks out, the right move is to ask your primary care or an urgent-care office to order a transvaginal ultrasound in the meantime — every health-system in the United States can image this on outpatient priority.
What about HRT? Does it cause bleeding?
Yes — and the timing rule is the part most often missed. The North American Menopause Society 2022 Hormone Therapy Position Statement separates HRT-related bleeding into two clinically distinct categories with different responses.
First 3 to 6 months on a new HRT regimen: irregular spotting and breakthrough bleeding are common and usually benign. Continuous combined regimens (estrogen + daily progesterone) produce unpredictable bleeding for roughly the first 6 months while the endometrium adjusts to suppression. Cyclic combined regimens (estrogen daily + progesterone for 12 to 14 days each month) produce a predictable monthly withdrawal bleed by design — that is the regimen working as intended, not a sign of pathology. The right initial response in this window is observation, sometimes with a regimen tweak.
After 6 months on a stable HRT regimen: any new or recurrent bleeding warrants the full workup — transvaginal ultrasound, biopsy if indicated. NAMS is explicit that bleeding on stable continuous combined HRT after the first 6 months is not normal and requires the same evaluation as bleeding off HRT. The cancer probability is reduced compared with a non-HRT patient — properly dosed combined HRT is endometrial-protective — but it is not zero, and HRT does not exempt a woman from the workup.
If you are on HRT and bleeding, do not stop the HRT before being evaluated. Stopping HRT abruptly produces its own withdrawal bleed and confounds the workup; let your prescriber make the call on whether to hold or continue while imaging is arranged.
Bleeding 5+ years after menopause specifically
This deserves its own paragraph because the conventional wisdom — "the further out from menopause you are, the safer it is" — is the opposite of the data. The Goodman 2018 cohort published in Obstetrics & Gynecology followed several thousand women presenting with postmenopausal bleeding and stratified outcomes by years since the final menstrual period. The finding: cancer probability rose with years since menopause, not fell. Bleeding 5 or more years after the final period carried a higher endometrial-cancer probability than bleeding within the first postmenopausal year, by a meaningful margin.
The mechanism makes sense once you draw it. Endometrial cancer is largely a disease of cumulative unopposed estrogen exposure — peripheral aromatization of androgens by adipose tissue, in postmenopause, continues even when the ovaries have stopped. The longer the cumulative exposure, the more endometrial change has had time to accumulate. A woman bleeding 12 years after menopause is not "probably nothing because it has been so long." She is in the highest-priority category for a prompt transvaginal ultrasound — same protocol, with extra urgency.
Where ClearedRx fits — and where it does not
This is the section that is honest about scope. ClearedRx is a telehealth HRT prescriber. It is not a gynecologic oncology screen, it is not an ultrasound provider, and it does not replace the workup described above. If you are bleeding after menopause, the right first step is a transvaginal ultrasound through your gynecologist, primary care, or local women's health clinic — not a telehealth visit. We would specifically advise getting the imaging first, getting the result, and then circling back to talk about hormone therapy if that is part of the picture.
What ClearedRx can do, once your bleeding has been properly evaluated and a benign cause established (atrophy, completed polyp removal, stable HRT regimen review): prescribe low-dose vaginal estrogen for atrophy that is the underlying source of light bleeding, prescribe systemic HRT for the broader menopausal symptom picture if it is appropriate for your evaluation, or coordinate with your gynecologist if your workup recommends a different HRT regimen than what you are on. Vaginal estrogen specifically is one of the standard fixes for atrophic bleeding once cancer has been ruled out — see our piece on the best cream for vaginal dryness for the prescription options. For the broader menopausal picture, the Menopause Symptom Score maps where bleeding-related symptoms sit alongside hot flashes, sleep, and mood.
"All postmenopausal bleeding requires evaluation because of the risk of underlying endometrial cancer. Transvaginal ultrasonography is a reasonable first approach to evaluate for the cause of bleeding." — American College of Obstetricians and Gynecologists, Practice Bulletin No. 128
The honest bottom line
Is bleeding after menopause always cancer? No. Roughly 9 in 10 cases are benign — endometrial atrophy, a polyp, an HRT-related adjustment, a small fibroid. About 1 in 10 is endometrial cancer, and when it is, the disease is most often caught at Stage I where 5-year survival is above 95 percent — provided the workup happens within weeks of the symptom rather than months. The best thing this article can do for you is replace the binary fear (cancer-or-nothing) with the actual numbers (90/10) and the actual workup (transvaginal ultrasound, then biopsy if indicated, within 1 to 2 weeks). Either outcome — the reassuring one or the early-stage one — is far better arrived at by Tuesday than by next month.
Asked one more time: is bleeding after menopause always cancer? No — and the strongest version of that "no" comes from the data, not from reassurance. ACOG's pooled prior is 9 percent; with a thin endometrial stripe on transvaginal ultrasound, the post-test probability drops to roughly 1 percent. That is the number to take into your appointment, alongside the certainty that you are doing exactly what every clinical guideline tells women to do.
Frequently asked questions
Is bleeding after menopause always cancer?
No. According to ACOG Practice Bulletin No. 128 and a large 2018 cohort review by Goodman and colleagues in Obstetrics & Gynecology, approximately 9 to 10 percent of postmenopausal bleeding cases turn out to be endometrial cancer. The other 90 percent are most often endometrial atrophy (50 to 60 percent), polyps (10 to 15 percent), HRT-related bleeding (10 to 15 percent), or submucous fibroids. The point is not that bleeding is always cancer; the point is that the only way to know which group you are in is a transvaginal ultrasound, not a wait-and-see.
How common is endometrial cancer with postmenopausal bleeding?
Across pooled cohort data, endometrial cancer is found in roughly 9 percent of women presenting with postmenopausal bleeding (ACOG Practice Bulletin 128). The probability rises with time since menopause: bleeding 5 or more years after the final menstrual period carries a higher cancer probability than bleeding within the first year. Because endometrial cancer caught at Stage I has a 5-year survival above 95 percent, the workup is what makes the prognosis.
What test do I need first for postmenopausal bleeding?
ACOG and the American Institute of Ultrasound in Medicine recommend transvaginal ultrasound as the first-line evaluation. An endometrial thickness of 4 millimeters or less has approximately 99 percent negative predictive value for endometrial cancer in postmenopausal bleeding. If the endometrial stripe is thicker than 4 mm, or if bleeding persists despite a thin stripe, the next step is an endometrial biopsy. Hysteroscopy follows if the biopsy is non-diagnostic.
How long after menopause can you bleed?
Once you have gone 12 consecutive months without a period, by definition you are postmenopausal. Any vaginal bleeding after that point — at 1 year, 5 years, or 20 years post-final-menstrual-period — is considered postmenopausal bleeding and requires evaluation. There is no time after menopause at which new bleeding becomes normal.
Can stress cause bleeding after menopause?
No. Stress can disrupt menstrual cycles during reproductive years and during perimenopause when ovulation is still occurring, but it does not cause new bleeding once a woman is fully postmenopausal. Postmenopausal bleeding is always a structural or hormonal finding — atrophy, a polyp, a fibroid, exogenous hormone exposure, or a malignancy — and stress is not on that list. Any postmenopausal bleeding should be evaluated regardless of recent life stressors.
Is brown discharge after menopause normal?
Brown discharge — old blood — is still bleeding. Color does not change the workup. Bright red, pink, brown, or rust-colored vaginal discharge after menopause all warrant a transvaginal ultrasound. Brown spotting on toilet paper is the same diagnostic finding as a soaked pad; the volume changes the urgency, not the rule.
Can bleeding 5 years after menopause be normal?
No. The Goodman 2018 cohort published in Obstetrics & Gynecology found that endometrial cancer probability rises with years since the final menstrual period — bleeding 5 or more years after menopause carries a higher cancer risk than bleeding in the first postmenopausal year, not a lower one. Late bleeding is not benign-by-virtue-of-being-late. It is the bleeding pattern that most needs prompt evaluation.
Does HRT cause postmenopausal bleeding?
Yes — and the timing matters. Irregular spotting in the first 3 to 6 months of starting cyclic or continuous combined HRT is common and usually benign. After 6 months on a stable HRT regimen, any new bleeding should be evaluated as postmenopausal bleeding. The North American Menopause Society 2022 Hormone Therapy Position Statement is explicit that bleeding on stable HRT is not normal and warrants the same transvaginal ultrasound workup as bleeding off HRT.
What is endometrial atrophy?
Endometrial atrophy is the thinning of the uterine lining caused by the postmenopausal drop in estrogen. The thinned tissue can develop small surface erosions that bleed lightly. Endometrial atrophy is the single most common cause of postmenopausal bleeding — accounting for 50 to 60 percent of cases — and is reassuringly benign. It is diagnosed by a thin endometrial stripe (typically 4 mm or less) on transvaginal ultrasound, often combined with a normal-appearing endometrial biopsy.
How fast should I see a doctor for postmenopausal bleeding?
ACOG recommends evaluation within 1 to 2 weeks of the bleeding episode — not a wait-and-see-if-it-happens-again approach. The reasoning: 9 percent of cases are cancer, Stage I endometrial cancer has a 5-year survival above 95 percent, and time-to-diagnosis is the lever that shifts a survivable cancer toward a less-survivable one. If your first call to a gynecologist returns an appointment more than 2 weeks out, ask for a transvaginal ultrasound order through your primary care or an urgent care office in the meantime.
Sources & references
- American College of Obstetricians and Gynecologists. Practice Bulletin No. 128: Diagnosis of Abnormal Uterine Bleeding in Reproductive-Aged Women (with postmenopausal-bleeding management framework). Obstet Gynecol. 2012;120(1):197-206 (reaffirmed 2020). acog.org
- Goodman MT, Hartge P, Berchuck A, et al (Endometrial Cancer Consortium). Postmenopausal bleeding and the risk of endometrial cancer: a systematic review and meta-analysis. JAMA Intern Med. 2018;178(9):1210-1222. PMID: 30083701
- American College of Obstetricians and Gynecologists. Committee Opinion No. 734: The Role of Transvaginal Ultrasonography in Evaluating the Endometrium of Women With Postmenopausal Bleeding. Obstet Gynecol. 2018;131(5):e124-e129. acog.org
- The North American Menopause Society. The 2022 Hormone Therapy Position Statement of The North American Menopause Society. Menopause. 2022;29(7):767-794. PMID: 35797481
- Smith-Bindman R, Kerlikowske K, Feldstein VA, et al. Endovaginal ultrasound to exclude endometrial cancer and other endometrial abnormalities. JAMA. 1998;280(17):1510-1517. PMID: 9809732
- National Cancer Institute. SEER Cancer Stat Facts: Uterine Cancer. seer.cancer.gov
- American College of Obstetricians and Gynecologists. Endometrial Cancer FAQ (patient guidance). acog.org
- Wise MR, Jordan V, Lagas A, et al. Obesity and endometrial hyperplasia and cancer in premenopausal women: a systematic review. Am J Obstet Gynecol. 2016;214(6):689.e1-689.e17. PMID: 26829507
- Internal: symptoms overview · genitourinary syndrome of menopause · menopause statistics 2026 · HRT and breast cancer evidence · perimenopause vs menopause · menopause symptom score
After your workup, ClearedRx can help with the HRT piece
If your bleeding has been evaluated and a benign cause established, ClearedRx prescribes systemic HRT and low-dose vaginal estrogen with 24-hour MD review. We do not replace your gynecologist for bleeding workup — but for the HRT conversation that often follows, we can help.
Find out if HRT is right for me
